Yin Kailin, Liu Yanchen, Chu Ming, Wang Yuedan
Department of Immunology, School of Basic Medical Science, Peking University, Beijing, China.
School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Liaoning, China.
PLoS One. 2017 Jan 23;12(1):e0170573. doi: 10.1371/journal.pone.0170573. eCollection 2017.
Breast cancer remains a lethal disease to women due to lymph node metastasis, the tumor microenvironment, secondary resistance and other unknown factors. Several important transcription factors involved in this disease, such as PTEN, p53 and beta-catenin, have been identified and researched in-depth as candidates for targeted therapy in breast cancer. TFDP3 is a new, promising candidate for transcriptional regulation in breast cancer, although it was first identified in hepatocellular carcinoma. Here, we demonstrate that TFDP3 is expressed in a variety of malignancies, normal testis tissue and breast cancer cell lines and thus provide evidence that TFDP3 is a cancer-testis antigen. We illustrate that overexpression or silencing TFDP3 interferes with epithelial-mesenchymal transition but does not influence cell proliferation, indicating that the TFDP3 protein acts as a transcription factor during epithelial-mesenchymal transition. These data highlight that TFDP3 is expressed in breast cancer, that it is a member of the cancer-testis antigen family and that it functions as a regulator in epithelial-mesenchymal transition.
由于淋巴结转移、肿瘤微环境、继发性耐药及其他未知因素，乳腺癌对女性而言仍然是一种致命疾病。一些参与该疾病的重要转录因子，如PTEN、p53和β-连环蛋白，已被确定并作为乳腺癌靶向治疗的候选因子进行了深入研究。TFDP3是乳腺癌转录调控中一个新的、有前景的候选因子，尽管它最初是在肝细胞癌中被发现的。在此，我们证明TFDP3在多种恶性肿瘤、正常睾丸组织及乳腺癌细胞系中表达，从而提供了TFDP3是一种癌-睾丸抗原的证据。我们表明，TFDP3的过表达或沉默会干扰上皮-间质转化，但不影响细胞增殖，这表明TFDP3蛋白在上皮-间质转化过程中作为一种转录因子发挥作用。这些数据突出表明，TFDP3在乳腺癌中表达，它是癌-睾丸抗原家族的一员，并在上皮-间质转化中作为一种调节因子发挥作用。
